EDL6D, a bioactive peptide phenocopying SHBG-associated metabolic effects: a new preclinical lead compound for treating the metabolic dysfunction-associated fatty liver disease - PubMed
a day ago
- #antifibrotic
- #bioactive peptide
- #MASLD treatment
- EDL6D is a bioactive peptide mimicking SHBG's metabolic effects and shows potential for treating metabolic dysfunction-associated fatty liver disease (MASLD).
- In preclinical studies, EDL6D reduced hepatic fat accumulation, inhibited lipogenic enzymes, and prevented mild fibrosis in MASLD models.
- The peptide downregulated key lipogenic factors like ATP-citrate lyase and peroxisome proliferator-activated receptor gamma, and reduced fibrosis markers such as Col1a1 and TGF-β1.
- EDL6D is identified as a novel preclinical lead compound targeting both lipid accumulation and fibrosis, supporting its translational potential for MASLD treatment.